This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
REGNPositive Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
by Sundeep Ganoria
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Biotech ETF (BBC) Hits New 52-Week High
by Sanghamitra Saha
Biotech ETF BBC hits a 52-week high amid renewed sector momentum, Fed rate cuts and AI-driven healthcare gains, hinting at more near-term upside.
BBCNegative Net Change
biotechs etfs
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
by Sundeep Ganoria
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
ANIPPositive Net Change AMRXPositive Net Change
biotechs medical
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
by Kanishka Das
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
REGNPositive Net Change BEAMNegative Net Change NTLAPositive Net Change CRSPNegative Net Change
biotechs
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
by Ekta Bagri
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
by Ekta Bagri
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
RHHBYPositive Net Change BMYPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
by Kanishka Das
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
IRWDPositive Net Change ABBVPositive Net Change PBYINegative Net Change
biotechs medical
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
by Ahan Chakraborty
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
by Zacks Equity Research
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
REGNPositive Net Change BEAMNegative Net Change NTLAPositive Net Change
biotechs cell-therapy crispr gene-editing gene-therapy medical pharmaceuticals
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
by Sundeep Ganoria
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
JAZZPositive Net Change TLRYNegative Net Change VRNONegative Net Change
biotechs marijuana medical pot-stocks
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYPositive Net Change JNJPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
by Zacks Equity Research
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
NVSPositive Net Change BAYRYNegative Net Change FOLDPositive Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
by Zacks Equity Research
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
SRPTPositive Net Change RNAPositive Net Change ARWRNegative Net Change PEPGNegative Net Change
biotechs gene-editing gene-therapy medical
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
by Zacks Equity Research
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
NVOPositive Net Change ADMANegative Net Change EDITNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
by Zacks Equity Research
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
BIIBPositive Net Change ADMANegative Net Change EDITNegative Net Change ARQTNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
by Ahan Chakraborty
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
by Sundeep Ganoria
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
by Kanishka Das
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
REGNPositive Net Change BEAMNegative Net Change NTLAPositive Net Change CRSPNegative Net Change
biotechs
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
AZNPositive Net Change MRKNegative Net Change ADMANegative Net Change EDITNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
by Zacks Equity Research
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
NVSPositive Net Change BAYRYNegative Net Change FOLDPositive Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals